Global Information
회사소개 | 문의 | 비교리스트

골수염 치료제 : 파이프라인 리뷰

Osteomyelitis - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 02월 상품 코드 474976
페이지 정보 영문 49 Pages
가격
US $ 2,000 ₩ 2,417,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,834,000 PDF by E-mail (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,251,000 PDF by E-mail (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


골수염 치료제 : 파이프라인 리뷰 Osteomyelitis - Pipeline Review, H1 2020
발행일 : 2020년 02월 페이지 정보 : 영문 49 Pages

골수염(Osteomyelitis) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업이나 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등을 정리하여 전해드립니다.

서론

  • 조사 범위

골수염 - 개요

골수염 - 치료제 개발

  • 파이프라인 개요
  • 기업별 파이프라인 동향
  • 기업에서 개발중인 제품

골수염 - 치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

골수염 치료제 개발 참여 기업

골수염 - 약제 프로파일

골수염 - 휴지 상태인 프로젝트

골수염 - 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

LSH 17.06.05

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Osteomyelitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Osteomyelitis - Pipeline by Allergan Plc, H1 2020
  • Osteomyelitis - Pipeline by BioVinc LLC, H1 2020
  • Osteomyelitis - Pipeline by Debiopharm International SA, H1 2020
  • Osteomyelitis - Pipeline by Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd, H1 2020
  • Osteomyelitis - Pipeline by Telephus Medical LLC, H1 2020
  • Osteomyelitis - Dormant Projects, H1 2020

List of Figures

  • Number of Products under Development for Osteomyelitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteomyelitis - Pipeline Review, H1 2020, provides an overview of the Osteomyelitis (Infectious Disease) pipeline landscape.

Osteomyelitis is an infection in a bone. Infections can reach a bone by traveling through the bloodstream or spreading from nearby tissue. Symptoms include fever, pain in the area of the infection, swelling, warmth and redness over the area of the infection and irritability. Risk factors bone fracture, sickle cell disease, chemotherapy, diabetes and peripheral arterial disease. Treatment includes surgery and oral antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteomyelitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Osteomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Osteomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 2 and 3 respectively.

Osteomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteomyelitis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Osteomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteomyelitis (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteomyelitis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

  • Global Markets Direct Report Coverage
  • Osteomyelitis - Overview
  • Osteomyelitis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Osteomyelitis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Osteomyelitis - Companies Involved in Therapeutics Development
  • Allergan Plc
  • BioVinc LLC
  • Debiopharm International SA
  • Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
  • Telephus Medical LLC
  • Osteomyelitis - Drug Profiles
  • afabicin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BV-600022 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ceforanide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dalbavancin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TPH-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Osteomyelitis - Dormant Projects
  • Osteomyelitis - Product Development Milestones
  • Featured News & Press Releases
  • Apr 12, 2018: Cardiome Announces Xydalba Abstracts at ECCMID 2018
  • Dec 11, 2017: Telephus Biosciences Appoints Patrick Vink, M.D., MBA, William Boyle, Ph.D., and Richard Proctor, M.D., as Company Advisors
  • Oct 24, 2016: Allergan to Present New Data on DALVANCE (dalbavancin) at IDWeek 2016 in New Orleans
  • Apr 08, 2016: Debiopharm International to present the latest findings on Debio 1450 at ECCMID
  • Oct 10, 2014: Durata Therapeutics Presents New Data for DALVANCE(TM) at IDWeek 2014
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q